New York, Nov 9 ,2020: Pfizer says an early peek at its vaccine data suggests the shots may be 90 per cent effective at preventing COVID-19, indicating the company is on track later this month to file an emergency use application with U.S. regulators.
Monday’s announcement doesn’t mean a vaccine is imminent: This interim analysis, from an independent data monitoring board, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people in the US and five other countries.
Pfizer Inc did not provide any more details about those cases, and cautioned the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual.
New Delhi, Oct 21,2020: India in the past 24 hours recorded 46,791 fresh COVID-19 cases, lowest in nearly three months, as per the Union Health Ministry update on Tuesday.
The number of deaths from the virus in the same period were counted at 587, the data shows.
With the new additions, the total number of cases have surged to 75,97,064 while the death toll reached 1,15,197.
According to the ministry, as many as 69,720 more patients were cured, taking the total number of recoveries to 67,33,328 in numbers and 88.63 in percentage.
The death rate stands at 1.52 per cent.
There are 7,48,538 active cases which comprises 9.85 per cent of the total caseload.
According to the Indian Council of Medical Research (ICMR), as many as 10,32,795 samples were tested in the past 24 hours.
BANGKOK Oct 17,2020: Thailand has recorded its first two locally transmitted cases of the coronavirus in more than one month, the COVID-19 administration center said on Saturday.
It said in its daily report that the cases were among two Myanmar nationals living near the border with Myanmar, where infections have been surging recently.
The two were tested on Oct. 13. They showed no symptoms but results were positive, the center said in the statement. The last known local case was in early September.
Oct 16,2020: Gilead Sciences Inc’s remdesivir had little or no effect on COVID-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
The antiviral medication, among the first to be used as a treatment for COVID-19, was one of the drugs recently used to treat U.S. President Donald Trump’s coronavirus infection.
The results are from WHO’s “Solidarity” trial, which evaluated the effects of four potential drug regimens, including remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, in 11,266 adult patients across more than 30 countries.
The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with COVID-19, the WHO said on Thursday.
Earlier this month, data from a U.S. study of remdesivir by Gilead showed the treatment cut COVID-19 recovery time by five days compared with patients who got a placebo in a trial comprising 1,062 patients.
“The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir,” Gilead told Reuters.
“We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design.”
WHO chief scientist Soumya Swaminathan said on Wednesday that during the study, hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but other trials continued in more than 500 hospitals and 30 countries.
“We’re looking at what’s next. We’re looking at monoclonal anti-bodies, we’re looking at immunomodulators and some of the newer anti-viral drugs that have been developed in the last few months,” Swaminathan said.
Remdesivir received emergency use authorization from the U.S. Food and Drug Administration on May 1, and has since been authorized for use in several countries.